Type II Anti-CD20 Antibody and BCL-2 Inhibitor Combination Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments involving anti-CD20 antibodies and Bcl-2 inhibitors often require multiple agents and complex dosing schedules, which can be cumbersome and may not fully leverage the synergistic effects of these therapies.
Innovation Solution
A combination therapy involving a type II anti-CD20 antibody, such as GA101, and a selective Bcl-2 inhibitor, like GDC-0199, administered in various dosing cycles to enhance antitumor activity, with the option to continue either agent monotherapy post-combination treatment for sustained efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If multiple agents and complex dosing schedules are used, then antitumor activity can be enhanced, but treatment complexity and ease of operation deteriorate
Solution Approach 1:
The patent combines a type II anti-CD20 antibody and a selective Bcl-2 inhibitor into a single therapeutic regimen, merging two previously separate treatments into one coordinated therapy that achieves synergistic antitumor effects while simplifying the overall treatment structure
Solution Approach 2:
The patent optimizes dosing parameters by establishing specific dosing cycles and frequency ranges (e.g., administering the antibody every 1-4 weeks and the inhibitor every 1-3 weeks), transforming complex individual dosing requirements into a standardized, simplified regimen that maintains therapeutic efficacy
2Reliability
If combination therapy is used, then tumor regression increases, but treatment duration and time consumption increase
Solution Approach 1:
The patent implements periodic dosing schedules where the anti-CD20 antibody is administered every 1-4 weeks and the Bcl-2 inhibitor every 1-3 weeks, creating optimized treatment cycles that maintain sustained therapeutic pressure on the tumor while allowing for appropriate pharmacokinetic intervals, thereby achieving effective tumor regression without unnecessarily extending total treatment duration
Data Source
AI summary
The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.